Edition:
United States

Cara Therapeutics Inc (CARA.OQ)

CARA.OQ on NASDAQ Stock Exchange Global Market

12.40USD
4:00pm EDT
Change (% chg)

$-0.08 (-0.64%)
Prev Close
$12.48
Open
$12.50
Day's High
$12.60
Day's Low
$12.18
Volume
220,936
Avg. Vol
471,317
52-wk High
$28.49
52-wk Low
$5.85

Latest Key Developments (Source: Significant Developments)

Cara Therapeutics Q2 loss per share $0.29
Thursday, 3 Aug 2017 04:01pm EDT 

Aug 3 (Reuters) - Cara Therapeutics Inc ::Cara Therapeutics reports second quarter 2017 financial results.Q2 loss per share $0.29.Q2 earnings per share view $-0.62 -- Thomson Reuters I/B/E/S.Cara-‍ expects existing cash, cash equivalents, available-for-sale marketable securities to be sufficient to fund operating expenses, capex requirements into 2019​.  Full Article

Cara Therapeutics appoints Mani Mohindru CFO
Tuesday, 1 Aug 2017 07:00am EDT 

Aug 1 (Reuters) - Cara Therapeutics Inc ::Cara Therapeutics appoints Mani Mohindru, Ph.D., chief financial officer.Josef Schoell, who has held CFO position at Cara for more than a decade, will be retiring.Most recently, Mohindru served as chief strategy officer at Curis, Inc.  Full Article

Cara Therapeutics says ‍phase 1 results showed all four tablet strengths of oral CR845 were generally well-tolerated​
Wednesday, 12 Jul 2017 07:00am EDT 

July 12 (Reuters) - Cara Therapeutics Inc :Cara Therapeutics announces summary data from phase 1 trial of oral cr845 in hemodialysis patients with chronic kidney disease.Cara Therapeutics Inc - ‍phase 1 results showed that all four tablet strengths of oral CR845 were generally well-tolerated​.Cara Therapeutics- ‍overall,frequency of treatment emergent adverse events (teaes) in CR845-treated patients was similar to group administered placebo​.Cara Therapeutics-data to inform design of planned oral CR845 pruritus clinical program in non-dialysis ckd-ap population aimed to initiate later this year.  Full Article

Cara Therapeutics announces top-line results from phase 2B trial
Thursday, 29 Jun 2017 04:01pm EDT 

June 29 (Reuters) - Cara Therapeutics Inc ::Cara Therapeutics announces top-line results from phase 2B trial of oral CR845 in chronic pain patients with osteoarthritis of the hip or knee.Cara Therapeutics Inc - all tablet strengths well tolerated over eight-week treatment period.Cara Therapeutics Inc - 35 percent reduction in mean joint pain score for all patients at eight weeks with 5.0 mg dose.Cara Therapeutics Inc - statistically significant 39 percent reduction in mean joint pain score in hip patients at eight weeks with 5.0 mg dose.  Full Article

Cara receives breakthrough therapy designation from FDA for I.V. CR845
Friday, 23 Jun 2017 07:00am EDT 

June 23 (Reuters) - Cara Therapeutics Inc ::Cara receives breakthrough therapy designation from FDA for I.V. CR845 for the treatment of chronic kidney disease-associated pruritus in hemodialysis patients.  Full Article

Cara Therapeutics reports continuation of phase 3 trial of I.V. CR845 in postoperative pain
Wednesday, 21 Jun 2017 07:00am EDT 

June 21 (Reuters) - Cara Therapeutics Inc ::Cara Therapeutics reports continuation of phase 3 trial of i.v. Cr845 in postoperative pain following interim assessment.Cara Therapeutics - ‍based on guidance of idmc, trial will continue to test 2 doses of cr845 versus placebo in up to 450 patients undergoing abdominal surgery​.Cara Therapeutics Inc - trial will continue to test two doses of cr845 and aims to enroll up to 450 patients.Cara Therapeutics Inc - both doses of cr845 well tolerated.Cara Therapeutics Inc - trial completion expected in q4 of 2017 for cr845.  Full Article

Cara Therapeutics Q1 loss per share $0.81
Thursday, 4 May 2017 04:01pm EDT 

May 4 (Reuters) - Cara Therapeutics Inc ::Cara Therapeutics reports first quarter 2017 financial results.Q1 loss per share $0.81.Q1 earnings per share view $-0.74 -- Thomson Reuters I/B/E/S.Cara Therapeutics Inc - expects existing cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements into 2019.Qtrly total revenue $911,000 versus $7,000.  Full Article

Cara Therapeutics announces positive data
Monday, 24 Apr 2017 07:00am EDT 

April 24 (Reuters) - Cara Therapeutics Inc ::Cara Therapeutics announces positive data from quantitative phase 1 trial measuring respiratory safety of I.V. CR845.Cara Therapeutics-trial showing that I.V. CR845 did not significantly differ from placebo across 3 quantitative measures of respiratory drive in healthy individuals.Cara Therapeutics - reported treatment-emergent adverse events were previously reported with CR845 administration; were mild, resolving without intervention.  Full Article

Cara Therapeutics prices 4.45 mln share offering at $18 per share
Thursday, 30 Mar 2017 09:35pm EDT 

Cara Therapeutics Inc : Cara Therapeutics announces pricing of its public offering of common stock .Says public offering of 4.45 million common shares priced at $18 per share.  Full Article

Cara Therapeutics announces proposed offering of common stock
Wednesday, 29 Mar 2017 04:01pm EDT 

Cara Therapeutics Inc : Cara Therapeutics announces proposed offering of common stock . Cara Therapeutics Inc - commenced an underwritten public offering of $80 million of shares of its common stock .Cara Therapeutics Inc - proceeds of offering are expected to be used to fund company's clinical and research development activities.  Full Article

BRIEF-Cara Therapeutics Q2 loss per share $0.29

* Cara Therapeutics reports second quarter 2017 financial results